Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 89 results for statins

  1. Whittington Health Pharmacy Re-ablement Service

    Mrs X was prescribed duplicate drugs within therapeutic groups including; statins, PPIs, Vitamin D supplementation and antibiotic...

  2. Endovascular stent insertion for intracranial atherosclerotic disease (IPG429)

    Evidence-based recommendations on endovascular stent insertion for intracranial atherosclerotic disease. This involves inflating a balloon catheter inserted into an artery in the arm or leg, and positioning a stent in the narrowing to maintain improved blood flow.

  3. Gastroparesis in adults: oral erythromycin (ESUOM13)

    Summary of the evidence on oral erythromycin for gastroparesis (delayed stomach emptying) in adults to inform local NHS planning and decision-making

  4. Stopping preventive medicines:- What is the clinical and cost effectiveness of stopping preventive medicines in people with multimorbidity who may not benefit from continuing them?

    multimorbidity. The review found 1 small randomised controlled trial of stopping statins in people with a life expectancy of 1 year, but...

  5. Improving baseline assessment for newly diagnosed hypertensive patients and optimising therapy

    early detection of patients that might benefit from primary prevention with statins and for GPs to have discussion with them. The...

  6. Transcervical extracorporeal reverse flow neuroprotection for reducing the risk of stroke during carotid artery stenting (IPG561)

    Evidence-based recommendations on transcervical extracorporeal reverse flow neuroprotection for reducing the risk of stroke during carotid artery stenting in adults. This involves reversing blood flow away from the brain and filtering the blood to remove any debris.

  7. Targeted-release budesonide for treating primary IgA nephropathy (TA937)

    Evidence-based recommendations on targeted-release budesonide (Kinpeygo) for treating primary immunoglobulin A (IgA) nephropathy in adults.

  8. Hypercholesterolaemia (primary), dyslipidaemia (mixed) - anacetrapib [ID1165]

    Discontinued [GID-TA11175]

  9. Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (TA223)

    Evidence-based recommendations on cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for treating intermittent claudication in adults with peripheral arterial disease.

  10. Statins for the prevention of cardiovascular events (TA94)

    This guidance has been updated and replaced by NICE guideline CG181.

  11. Optowire for measuring fractional flow reserve (MIB199)

    NICE has developed a medtech innovation briefing (MIB) on Optowire for measuring fractional flow reserve .

  12. Gout: diagnosis and management (NG219)

    This guideline covers the diagnosis and management of gout. It includes recommendations on diagnosing gout, managing flares, long-term management of gout and referral to specialist services.

  13. Diabetes in pregnancy: management from preconception to the postnatal period (NG3)

    This guideline covers managing diabetes and its complications in women who are planning pregnancy or are already pregnant. It aims to improve the diagnosis of gestational diabetes and help women with diabetes to self-manage their blood glucose levels before and during pregnancy.

  14. Ticagrelor for the treatment of acute coronary syndromes (TA236)

    Evidence-based recommendations on ticagrelor (Brilique) for treating acute coronary syndromes in adults.

  15. Chronic kidney disease: assessment and management (NG203)

    This guideline covers care and treatment for people with, or at risk of, chronic kidney disease (CKD). It aims to prevent or delay the progression, and reduce the risk of complications and cardiovascular disease. It also covers managing anaemia and hyperphosphataemia associated with CKD.